



February 8, 2024

Name of Company: Meiji Holdings Co., Ltd.
Name of Representative: Kazuo Kawamura, CEO, President and Representative Director
Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning Amendment to Earnings Report of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ended March 31, 2023

Meiji Holdings Co., Ltd. announces that we amend its Earnings Report and Supplementary Explanatory Data of Consolidated Financial Results for the Third Quarter of the Fiscal Year Ended March 31, 2023 [Based on Japanese GAAP], announced on February 9, 2023. This is to amend the amount of elimination of operating profit of certain businesses in the pharmaceutical segment. We also announce that no correction has been made to the numerical data. The amendments are as follows (underlined):

Description

- 1. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ended March 31, 2023**
[Based on Japanese GAAP] on page 9
1. Qualitative Information
 - 1) Explanation Concerning Operating Results
 - (2) Pharmaceutical segment

<Before the amendment> (Billions of yen)

Net sales				Operating profit			
For the first nine months ended December 31	2021	2022	% Change	For the first nine months ended December 31	2021	2022	% Change
Domestic ethical pharmaceuticals	66.5	73.5	10.4%	Domestic ethical pharmaceuticals	3.1	9.3	201.6%
Overseas ethical pharmaceuticals	29.1	38.9	33.5%	Overseas ethical pharmaceuticals	2.9	6.2	116.2%
Human vaccines	37.2	28.1	-24.5%	Human vaccines	13.0	<u>4.8</u>	<u>-62.9%</u>
Agricultural chemicals& veterinary drugs	11.3	8.0	-29.0%	Agricultural chemicals& veterinary drugs	-0.6	<u>0.5</u>	—

Disclaimer: This English translation is prepared for the readers' convenience. When there are any discrepancies between the original Japanese version and English translation version, the original Japanese version always prevails.

<After the amendment>

(Billions of yen)

Net sales				Operating profit			
For the first nine months ended December 31	2021	2022	% Change	For the first nine months ended December 31	2021	2022	% Change
Domestic ethical pharmaceuticals	66.5	73.5	10.4%	Domestic ethical pharmaceuticals	3.1	9.3	201.6%
Overseas ethical pharmaceuticals	29.1	38.9	33.5%	Overseas ethical pharmaceuticals	2.9	6.2	116.2%
Human vaccines	37.2	28.1	-24.5%	Human vaccines	13.0	<u>4.2</u>	<u>-67.5%</u>
Agricultural chemicals& veterinary drugs	11.3	8.0	-29.0%	Agricultural chemicals& veterinary drugs	-0.6	<u>1.1</u>	—

2. Supplementary Explanatory Data on page 5

2. Segment Information

2. Pharmaceutical Segment

B. Operating Profit

<Before the amendment>

(Billions of yen)

FYE March 2023	Q1-Q3		
		YoY change	Full-year plan achievement rate
		%	%
Domestic ethical pharmaceuticals	9.3	+201.6%	123.2
Overseas ethical pharmaceuticals	6.2	+116.2%	85.1
Human vaccines	<u>4.8</u>	<u>-62.9%</u>	<u>130.9</u>
Veterinary drugs	<u>0.5</u>	—	<u>40.9</u>

<After the amendment>

(Billions of yen)

FYE March 2023	Q1-Q3		
		YoY change	Full-year plan achievement rate
		%	%
Domestic ethical pharmaceuticals	9.3	+201.6%	123.2
Overseas ethical pharmaceuticals	6.2	+116.2%	85.1
Human vaccines	<u>4.2</u>	<u>-67.5%</u>	<u>114.7</u>
Veterinary drugs	<u>1.1</u>	—	<u>87.1</u>

#####